Post-transcriptional up-regulation of PDGF-C by HuR in advanced and stressed breast cancer

International Journal of Molecular Sciences

Volumn 15, Issue 11, 2014, Pages 20306-20320

  Luo, Nian An ^a,b   Qu, Ya Qi ^a   Yang, Guo Dong ^c   Wang, Tao ^c   Li, Ren Li ^a   Jia, Lin Tao ^c   Dong, Rui ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b Department of General Surgery 10 Hospital of People s Liberation Army (PLA)   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Breast neoplasms; HuR; MRNA stability; Platelet derived growth factor C (PDGF C)

Indexed keywords

HUR PROTEIN; PLATELET DERIVED GROWTH FACTOR C; 3' UNTRANSLATED REGION; ELAV PROTEIN; LYMPHOKINE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR; PLATELET-DERIVED GROWTH FACTOR C;

ADULT; ARTICLE; AU RICH ELEMENT; BREAST CANCER; CANCER STAGING; CELL INVASION ASSAY; CELL PROLIFERATION; CELL STRESS; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GENETIC ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; LUCIFERASE ASSAY; MAJOR CLINICAL STUDY; MTT ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA PROCESSING; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING; 3' UNTRANSLATED REGION; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGICAL STRESS; PROGNOSIS; RNA STABILITY; TUMOR CELL LINE;

3' UNTRANSLATED REGIONS; BREAST NEOPLASMS; CELL LINE, TUMOR; ELAV PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHOKINES; MIDDLE AGED; NEOPLASM STAGING; PLATELET-DERIVED GROWTH FACTOR; PROGNOSIS; RNA STABILITY; RNA, MESSENGER; STRESS, PHYSIOLOGICAL; TRANSCRIPTION, GENETIC; UP-REGULATION;

EID: 84910107534     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms151120306     Document Type: Article

References (36)

1. Kolch, W.; Pitt, A. Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat. Rev. Cancer 2010, 10, 618-629.
2. Montemurro, F.; di Cosimo, S.; Arpino, G. Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: New insights into molecular interactions and clinical implications. Ann. Oncol. 2013, 24, 2715-2724.
3. Hurst, N.J.; Najy, A.J.; Ustach, C.V.; Movilla, L.; Kim, H.R. Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: Implications for breast cancer progression. Biochem. J. 2012, 441, 909-918.
4. Reigstad, L.J.; Varhaug, J.E.; Lillehaug, J.R. Structural and functional specificities of PDGF-C and PDGF-D, the novel members of the platelet-derived growth factors family. FEBS J. 2005, 272, 5723-5741.
5. Lewis, N.L. The platelet-derived growth factor receptor as a therapeutic target. Curr. Oncol. Rep. 2007, 9, 89-95.
6. Yu, J.; Ustach, C.; Kim, H.R. Platelet-derived growth factor signaling and human cancer. J. Biochem. Mol. Biol. 2003, 36, 49-59.
7. Frings, O.; Augsten, M.; Tobin, N.P.; Carlson, J.; Paulsson, J.; Pena, C.; Olsson, E.; Veerla, S.; Bergh, J.; Ostman, A.; et al. Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling. Am. J. Pathol. 2013, 182, 2037-2047.
8. Son, D.; Na, Y.R.; Hwang, E.S.; Seok, S.H. Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad phosphorylation. J. Biol. Chem. 2014, 289, 6225-6235.
9. Atkinson, T.J.; Halfon, M.S. Regulation of gene expression in the genomic context. Comput. Struct. Biotechnol. J. 2014, 9, e201401001.
10. Fabian, M.R.; Sonenberg, N.; Filipowicz, W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 2010, 79, 351-379.
11. Aparicio, L.A.; Abella, V.; Valladares, M.; Figueroa, A. Posttranscriptional regulation by RNA-binding proteins during epithelial-to-mesenchymal transition. Cell. Mol. Life Sci. 2013, 70, 4463-4477.
12. Abdelmohsen, K.; Gorospe, M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip. Rev. RNA 2010, 1, 214-229.
13. Ma, W.J.; Cheng, S.; Campbell, C.; Wright, A.; Furneaux, H. Cloning and characterization of HuR, a ubiquitously expressed Elav-like protein. J. Biol. Chem. 1996, 271, 8144-8151.
14. Fan, X.C.; Steitz, J.A. Overexpression of HuR, a nuclear-cytoplasmic shuttling protein, increases the in vivo stability of ARE-containing mRNAs. EMBO J. 1998, 17, 3448-3460.
15. Gallouzi, I.E.; Steitz, J.A. Delineation of mRNA export pathways by the use of cell-permeable peptides. Science 2001, 294, 1895-1901.
16. Nathanson, K.L.; Wooster, R.; Weber, B.L. Breast cancer genetics: What we know and what we need. Nat. Med. 2001, 7, 552-556.
17. Govindaraju, S.; Lee, B.S. Adaptive and maladaptive expression of the mRNA regulatory protein HuR. World J. Biol. Chem. 2013, 4, 111-118.
18. Amadio, M.; Scapagnini, G.; Laforenza, U.; Intrieri, M.; Romeo, L.; Govoni, S.; Pascale, A. Post-transcriptional regulation of HSP70 expression following oxidative stress in SH-SY5Y cells: The potential involvement of the RNA-binding protein HuR. Curr. Pharm. Des. 2008, 14, 2651-2658.
19. Akaike, Y.; Masuda, K.; Kuwano, Y.; Nishida, K.; Kajita, K.; Kurokawa, K.; Satake, Y.; Shoda, K.; Imoto, I.; Rokutan, K. HuR regulates alternative splicing of the TRA2β gene in human colon cancer cells under oxidative stress. Mol. Cell Biol. 2014, 34, 2857-2873.
20. Bruland, O.; Fluge, O.; Akslen, L.A.; Eiken, H.G.; Lillehaug, J.R.; Varhaug, J.E.; Knappskog, P.M. Inverse correlation between PDGFC expression and lymphocyte infiltration in human papillary thyroid carcinomas. BMC Cancer 2009, 9, 425.
21. Denkert, C.; Weichert, W.; Winzer, K.J.; Muller, B.M.; Noske, A.; Niesporek, S.; Kristiansen, G.; Guski, H.; Dietel, M.; Hauptmann, S. Expression of the ELAV-like protein HuR is associated with higher tumor grade and increased cyclooxygenase-2 expression in human breast carcinoma. Clin. Cancer Res. 2004, 10, 5580-5586.
22. Li, X.; Kumar, A.; Zhang, F.; Lee, C.; Li, Y.; Tang, Z.; Arjuna, P. VEGF-independent angiogenic pathways induced by PDGF-C. Oncotarget 2010, 1, 309-314.
23. Fan, J.; Ishmael, F.T.; Fang, X.; Myers, A.; Cheadle, C.; Huang, S.K.; Atasoy, U.; Gorospe, M.; Stellato, C. Chemokine transcripts as targets of the RNA-binding protein HuR in human airway epithelium. J. Immunol. 2011, 186, 2482-2494.
24. Wang, W.; Caldwell, M.C.; Lin, S.; Furneaux, H.; Gorospe, M. HuR regulates cyclin A and cyclin B1 mRNA stability during cell proliferation. EMBO J. 2000, 19, 2340-2350.
25. Wang, J.; Zhao, W.; Guo, Y.; Zhang, B.; Xie, Q.; Xiang, D.; Gao, J.; Wang, B.; Chen, Z. The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis. Oncol. Basel 2009, 76, 420-429.
26. Al-Ahmadi, W.; Al-Ghamdi, M.; Al-Souhibani, N.; Khabar, K.S. miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer. J. Pathol. 2013, 230, 28-38.
27. Wang, J.; Wang, B.; Bi, J.; Zhang, C. Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer. Med. Oncol. 2011, 28, S577-S585.
28. Zhu, Z.; Wang, B.; Bi, J.; Zhang, C.; Guo, Y.; Chu, H.; Liang, X.; Zhong, C.; Wang, J. Cytoplasmic HuR expression correlates with P-gp, HER-2 positivity, and poor outcome in breast cancer. Tumor Biol. 2013, 34, 2299-2308.
29. Atasoy, U.; Watson, J.; Patel, D.; Keene, J.D. ELAV protein HuA (HuR) can redistribute between nucleus and cytoplasm and is up-regulated during serum stimulation and T cell activation. J. Cell Sci. 1998, 111, 3145-3156.
30. Wang, W.; Furneaux, H.; Cheng, H.; Caldwell, M.C.; Hutter, D.; Liu, Y.; Holbrook, N.; Gorospe, M. HuR regulates p21 mRNA stabilization by UV light. Mol. Cell Biol. 2000, 20, 760-769.
31. Wang, W.; Fan, J.; Yang, X.; Furer-Galban, S.; Lopez, D.S.I.; von Kobbe, C.; Guo, J.; Georas, S.N.; Foufelle, F.; Hardie, D.G., et al. AMP-activated kinase regulates cytoplasmic HuR. Mol. Cell Biol. 2002, 22, 3425-3436.
32. Lafarga, V.; Cuadrado, A.; Lopez, D.S.I.; Bengoechea, R.; Fernandez-Capetillo, O.; Nebreda, A.R. p38 Mitogen-activated protein kinase-and HuR-dependent stabilization of p21Cip1 mRNA mediates the G1/S checkpoint. Mol. Cell Biol. 2009, 29, 4341-4351.
33. Bouwman, P.; Jonkers, J. The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance. Nat. Rev. Cancer 2012, 12, 587-598.
34. Mazevet, M.; Moulin, M.; Llach-Martinez, A.; Chargari, C.; Deutsch, E.; Gomez, A.M.; Morel, E. Complications of chemotherapy, a basic science update. Presse Med. 2013, 42, e352-e361.
35. Hubenak, J.R.; Zhang, Q.; Branch, C.D.; Kronowitz, S.J. Mechanisms of injury to normal tissue after radiotherapy: A review. Plast. Reconstr. Surg. 2014, 133, 49e-56e.
36. Midgley, V.C.; Khachigian, L.M. Fibroblast growth factor-2 induction of platelet-derived growth factor-C chain transcription in vascular smooth muscle cells is ERK-dependent but not JNK-dependent and mediated by Egr-1. J. Biol. Chem. 2004, 279, 40289-40295.